Effects of Chrysin Supplementation on Blood and Urinary Testosterone Levels in Human: 2974: Board #273 June 3 3:30 PM - 5:00 PM

Hung, Tzu-Hsiang; Lin, Yi-An; Hsu, Ku-Fu; Lu, Ching-Yi; Hsu, Mei-Chich FACSM

Medicine & Science in Sports & Exercise: May 2011 - Volume 43 - Issue 5 - p 845
doi: 10.1249/01.MSS.0000402366.62833.64
F-36 Free Communication/Poster - Supplements III (Creatine, Sodium Bicarbonate, Others): JUNE 3, 2011 1:00 PM - 6:00 PM: ROOM: Hall B

National Taiwan Sport University, Taoyuan County, Taiwan. (Sponsor: NSC 97-2410-H-179-002 and NSC 98-2410-H-179-008, FACSM)

(No relationships reported)

In human, aromatase converts androstenedione and testosterone into estrone and estradiol, respectively. Chrysin has been shown as a potent aromatase inhibitor, which may increase the concentration of serum and urinary testosterone and lead to violate the doping control rule. However, the effects of the chrysin supplementation on blood and urinary testosterone levels in human have yet to be elucidated.

PURPOSE: This study was to investigate whether the chrysin supplementation would increase serum testosterone by altering the synthesis of the testosterone pathway. Moreover, the ratio of testosterone to epitestosterone in urine was measured.

METHODS: Twenty throwing athletes (14 males, 6 females) of National Taiwan Sport University participated in this study. Subjects were randomly assigned in pairs (matched for athletic events) by use of a double blind design to receive chrysin (group C) or placebo (group P). All subjects were oral 3,000 mg of chrysin capsules or equal dosage of placebo per day for 21 days. Blood and urine samples were collected at day 1, 8, and 22 in the morning after overnight fasting. Blood samples were analyzed for serum testosterone, free testosterone, and estradiol. Urinary testosterone and epitestosterone was measured by GC/MS. A two-way mixed designed analysis of variance (ANOVA), with one within-subject factor (time trial), one between-subject factor (group C or P), and their interaction, was used to determine the overall 21-day treatment effect and level of significance. All values were expressed as the mean ± SD. Values of P<0.05 were considered significant.

RESULTS: The data showed no significant difference in blood biomarkers between the groups C and P (testosterone: 4.7±2.3 vs. 4.3±1.6 ng/mL; free testosterone: 12.5±5.5 vs. 11.4± 3.5 pg/mL; estradiol: 43.2±22.1 vs. 49.6±18.7 pg/mL, p >.05). Urinary data of testosterone/epitestosterone ratio was less than 4.

CONCLUSION: Our data demonstrated that chrysin supplementation for 21 days may not increase serum and urinary testosterone levels.

© 2011 American College of Sports Medicine